

ASX ANNOUNCEMENT

ADMEDUS EXPANDS DISTRIBUTION AGREEMENT WITH CORONEO

- Admedus expands distribution agreement with CORONEO Inc to sell Extra-Aortic Annuloplasty Ring in Australia and New Zealand
- Partnership uses Admedus' existing sales, marketing and distribution infrastructure
- Announcement builds on original agreement to distribute CORONEO products in UK and Germany

Brisbane, Australia 8th of April 2016

Admedus has today announced that it has expanded its exclusive distribution partnership with CORONEO to sell its Extra-Aortic Annuloplasty Ring and related products in Australia and New Zealand. Admedus anticipates gaining marketing approval for this unique aortic implant in the second half of 2016.

"We are pleased to build on our existing partnership with CORONEO to distribute their leading aortic ring in Australia and New Zealand. This will be an extension to the current arrangement we have for the UK and Germany and fits well within our existing sales team. There is a natural synergy between the Extra-Aortic Ring and our product CardioCel[®], and we view this as a beneficial relationship in the lead up to CardioCel being approved in the Australian market," said Admedus CEO Mr Lee Rodne.

The CORONEO Extra-Aortic Ring is the first specially-designed aortic annuloplasty ring on the market used to surgically repair the Aortic valve and complements the use of CardioCel in heart valve repairs as Admedus expands its presence in the heart valve repair market. CardioCel was recently featured in a presentation at the Heart Valve Society meeting in New York, which highlighted that CardioCel[®] demonstrated the closest profile to native aortic valves, rendering it best suited for aortic valve reconstructions.

"We will continue to look to build revenue across the business, through our existing product portfolio's and through partnerships across our own technologies and complementary technologies from other companies," said Mr Rodne.

In October 2015, Admedus also initiated a post-market clinical study using CardioCel to reconstruct aortic valves in 80 patients across four leading heart centres in the US and Europe. The study is designed to illustrate the utility and benefits of CardioCel in aortic valve reconstruction over valve replacements. Patients in the clinical study will be reviewed 6, 12 and 24 months post-surgery to evaluate safety data and primary and secondary endpoints.

CardioCel is marketed in the USA, Europe, Canada, Singapore, Hong Kong and Malaysia and has been used in over 145 centres globally and has been implanted in over 4000 patients.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 (0)8 9266 0100

Media:

Shevaun Cooper | PR Manager | Admedus Limited

Tel: +61 (0) 417 985 599 | Email: scooper@admedus.com

Media Europe

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

US Investor

Rx Communications Group, LLC

Melody A. Carey

+1 917 322 2571

mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com

About CardioCel®

CardioCel is a type of cardiovascular bio-scaffold that can be used to repair congenital heart deformities and more complex heart defects. It is used to repair diseased paediatric and adult hearts. These repairs range from routine hole-in-the-heart operations to major vessel outflow tract repairs. The CardioCel scaffold may also be used to repair heart valves. CardioCel has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration, suggesting that the product facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue. CardioCel is the Admedus Group's lead regenerative tissue bio-implant used in repairing heart defects, including the repair of heart valves. It is engineered via

the Admedus Group's proprietary ADAPT™ tissue engineering process to produce a durable, collagen scaffold with handling properties preferred by surgeons that avoids calcification, while supporting native cell infiltration, growth and differentiation. CardioCel is a registered trademark.

About CORONEO

CORONEO Inc., a Canadian company, conducts research, development, and product commercialization of medical devices for the field of Cardiac Surgery. Since its inception in 1997, the company has rapidly become a noteworthy provider of premium, high-value surgical instruments and unique implantable devices that achieve cost-effective and less-invasive surgical procedures.

In addition to its Extra-Aortic Ring, the company is currently developing complementary implants to strengthen its leadership position in aortic valve repair surgery.

CORONEO's Extra-Aortic Ring was developed in partnership with Dr Emmanuel Lansac, the inventor of external aortic annuloplasty. Dr. Lansac was the principal investigator in a large, prospective multi-centre clinical trial (CAVIAAR) comparing aortic valve repair with the Extra-Aortic Ring to aortic valve replacement with a mechanical valved-conduit (Bentall procedure). A recognized global opinion leader at the forefront of driving surgical aortic valve reconstruction and repair techniques, Dr. Lansac practices at the Institut Mutualiste Montsouris in Paris, France, and is chairman of AVIATOR; an international working group created through the Heart Valve Society that is dedicated to the advancement of aortic valve repair.

Further information on the company may be found at www.coroneo.com